Drug Trial Radar · NCT01939366
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
699
Actual
Start
Sep 27, 2013
Primary completion
Jan 2015
Study completion Jan 28, 2015
Sponsor
- Lead sponsor
- Tris Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to evaluate if cebranopadol is safe and can decrease pain in patients when compared to placebo (a tablet that does not contain active product) and when compared to a marketed product containing pregabalin (Lyrica®). Furthermore, this trial will be undertaken to find out if the patient's general health and well-being improves under trial treatment. The concentrations of cebranopadol in the blood will be investigated to get a better understanding of how it is absorbed from the gut, distributed and broken down in the body, and eliminated from the body.
Conditions
- Chronic Pain
- Diabetic Neuropathies
- Diabetes Mellitus
Interventions
Cebranopadol 100 µgDrug
Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
Cebranopadol 300 µgDrug
Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
Cebranopadol 600 µgDrug
Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
PregabalinDrug
Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
Matching PlaceboDrug
Placebo will be matched to pregabalin and cebranopadol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Average Pain Intensity.Time frame: Baseline; to End of Week 6 of the Maintenance Phase
Locations
82 sites in 8 countries. Site status is shown where the registry gives one.
US002
Mesa, Arizona
US001
Garden Grove, California
US019
Laguna Hills, California
US014
National City, California
US007
Orange, California
US011
Hialeah, Florida
US012
Miami, Florida
US009
Orlando, Florida
US004
Blackfoot, Idaho
US006
Elgin, Illinois
US016
West Long Branch, New Jersey
US008
Brooklyn, New York
US005
Brooklyn, New York
US021
New York, New York
US003
West Jordan, Utah
AT007
Graz, Austria
AT005
Salzburg, Austria
AT004
Senftenberg, Austria
AT002
Vienna, Austria
AT003
Vienna, Austria
AT001
Vienna, Austria
AT006
Vienna, Austria
DK005
Aalborg, Denmark
DK003
Aarhus, Denmark
DK002
Copenhagen, Denmark
DK001
Odense, Denmark
FR008
Corbeil-Essonnes, France
FR001
Lille, France
FR007
Limoges, France
FR005
Montauban, France
FR002
Nantes, France
FR004
Orléans, France
FR006
Paris, France
DE018
Aschaffenburg, Germany
DE003
Bad Oeynhausen, Germany
DE005
Berlin, Germany
DE023
Berlin, Germany
DE031
Berlin, Germany
DE004
Berlin, Germany
DE025
Berlin, Germany
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.